Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Alternative dosing regimens for atezolizumab: right dose, wrong frequency.

Goldstein DA, Ratain MJ.

Cancer Chemother Pharmacol. 2019 Oct 19. doi: 10.1007/s00280-019-03971-7. [Epub ahead of print]

PMID:
31630223
2.

Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis.

Shlomai A, Leshno M, Goldstein DA.

Therap Adv Gastroenterol. 2019 Sep 23;12:1756284819878304. doi: 10.1177/1756284819878304. eCollection 2019.

3.

The Utility of Lyme Testing in the Workup of Ocular Inflammation.

Rifkin LM, Vadboncoeur J, Minkus CC, Dunn EN, Moorthy RS, Bhatt N, Sen HN, Taggart MG, Vitale AT, Goldstein DA.

Ocul Immunol Inflamm. 2019 Oct 2:1-5. doi: 10.1080/09273948.2019.1657904. [Epub ahead of print] No abstract available.

PMID:
31577476
4.

Transgender and Nontrans Patients Do Not Receive Statistically Different Quality Primary Care at Whitman-Walker Health, 2008-2016.

Goldstein DA, Sarkodie E, Hardy WD.

Transgend Health. 2019 Sep 23;4(1):200-208. doi: 10.1089/trgh.2019.0022. eCollection 2019.

5.

Treatment impact on recidivism of family only vs. generally violent partner violence perpetrators.

Cantos AL, Kosson DS, Goldstein DA, O'Leary KD.

Int J Clin Health Psychol. 2019 Sep;19(3):171-180. doi: 10.1016/j.ijchp.2019.05.002. Epub 2019 Jun 24.

6.

Should every candidate for cataract extraction be scheduled to the preoperative clinic? The Rabin Medical Center experience.

Gabbay IE, Gabbay U, Goldstein DA, Nahum Y.

Eur J Ophthalmol. 2019 Jul 29:1120672119865842. doi: 10.1177/1120672119865842. [Epub ahead of print]

PMID:
31353952
7.

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Ben-Aharon O, Magnezi R, Leshno M, Goldstein DA.

Oncologist. 2019 Jul 18. pii: theoncologist.2019-0175. doi: 10.1634/theoncologist.2019-0175. [Epub ahead of print]

PMID:
31320502
8.

Measurement-based care implementation in a Veterans Affairs primary care-mental health integration program.

Goldstein DA, Meyers K, Endsley M, Zerth EO.

Psychol Serv. 2019 Jul 18. doi: 10.1037/ser0000370. [Epub ahead of print]

PMID:
31318239
9.

The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States.

Moore A, Den RB, Gordon N, Sarfaty M, Kundel Y, Brenner B, Goldstein DA.

Clin Colorectal Cancer. 2019 Sep;18(3):209-217. doi: 10.1016/j.clcc.2019.05.005. Epub 2019 May 31.

PMID:
31255477
10.

Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment.

Ratain MJ, Goldstein DA, Lichter AS.

JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1341. [Epub ahead of print] No abstract available.

PMID:
31219513
11.

Cosmological Constraints from Multiple Probes in the Dark Energy Survey.

Abbott TMC, Alarcon A, Allam S, Andersen P, Andrade-Oliveira F, Annis J, Asorey J, Avila S, Bacon D, Banik N, Bassett BA, Baxter E, Bechtol K, Becker MR, Bernstein GM, Bertin E, Blazek J, Bridle SL, Brooks D, Brout D, Burke DL, Calcino J, Camacho H, Campos A, Carnero Rosell A, Carollo D, Carrasco Kind M, Carretero J, Castander FJ, Cawthon R, Challis P, Chan KC, Chang C, Childress M, Crocce M, Cunha CE, D'Andrea CB, da Costa LN, Davis C, Davis TM, De Vicente J, DePoy DL, DeRose J, Desai S, Diehl HT, Dietrich JP, Dodelson S, Doel P, Drlica-Wagner A, Eifler TF, Elvin-Poole J, Estrada J, Evrard AE, Fernandez E, Flaugher B, Foley RJ, Fosalba P, Frieman J, Galbany L, García-Bellido J, Gatti M, Gaztanaga E, Gerdes DW, Giannantonio T, Glazebrook K, Goldstein DA, Gruen D, Gruendl RA, Gschwend J, Gutierrez G, Hartley WG, Hinton SR, Hollowood DL, Honscheid K, Hoormann JK, Hoyle B, Huterer D, Jain B, James DJ, Jarvis M, Jeltema T, Kasai E, Kent S, Kessler R, Kim AG, Kokron N, Krause E, Kron R, Kuehn K, Kuropatkin N, Lahav O, Lasker J, Lemos P, Lewis GF, Li TS, Lidman C, Lima M, Lin H, Macaulay E, MacCrann N, Maia MAG, March M, Marriner J, Marshall JL, Martini P, McMahon RG, Melchior P, Menanteau F, Miquel R, Mohr JJ, Morganson E, Muir J, Möller A, Neilsen E, Nichol RC, Nord B, Ogando RLC, Palmese A, Pan YC, Peiris HV, Percival WJ, Plazas AA, Porredon A, Prat J, Romer AK, Roodman A, Rosenfeld R, Ross AJ, Rykoff ES, Samuroff S, Sánchez C, Sanchez E, Scarpine V, Schindler R, Schubnell M, Scolnic D, Secco LF, Serrano S, Sevilla-Noarbe I, Sharp R, Sheldon E, Smith M, Soares-Santos M, Sobreira F, Sommer NE, Swann E, Swanson MEC, Tarle G, Thomas D, Thomas RC, Troxel MA, Tucker BE, Uddin SA, Vielzeuf P, Walker AR, Wang M, Weaverdyck N, Wechsler RH, Weller J, Yanny B, Zhang B, Zhang Y, Zuntz J; DES Collaboration.

Phys Rev Lett. 2019 May 3;122(17):171301. doi: 10.1103/PhysRevLett.122.171301.

12.

OCT Angiography Imaging in Serpiginous Choroidopathy.

Desai R, Nesper P, Goldstein DA, Fawzi AA, Jampol LM, Gill M.

Ophthalmol Retina. 2018 Apr;2(4):351-359. doi: 10.1016/j.oret.2017.07.023. Epub 2017 Oct 19.

PMID:
31047244
13.

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer.

Gershon N, Berchenko Y, Hall PS, Goldstein DA.

Cost Eff Resour Alloc. 2019 Feb 28;17:5. doi: 10.1186/s12962-019-0174-7. eCollection 2019.

14.

The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.

Moore A, Stav I, Den RB, Gordon N, Sarfaty M, Neiman V, Rosenbaum E, Goldstein DA.

J Oncol. 2019 Jan 2;2019:8170428. doi: 10.1155/2019/8170428. eCollection 2019.

15.

A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.

Reinhorn D, Sarfaty M, Leshno M, Moore A, Neiman V, Rosenbaum E, Goldstein DA.

Oncologist. 2019 Mar;24(3):366-371. doi: 10.1634/theoncologist.2018-0656. Epub 2019 Feb 1.

PMID:
30710066
16.

Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review.

Mitchell AP, Rotter JS, Patel E, Richardson D, Wheeler SB, Basch E, Goldstein DA.

JAMA Oncol. 2019 Jun 1;5(6):893-899. doi: 10.1001/jamaoncol.2018.6196.

PMID:
30605222
17.

Partial Scleral Rupture Presenting 4 Years After Laser in Situ Keratomileusis.

LaMattina KC, Feder RS, Koreishi AF, Goldstein DA.

Cornea. 2019 Apr;38(4):498-501. doi: 10.1097/ICO.0000000000001850.

PMID:
30601290
18.

Moving From Syndromic Description to Etiologic Diagnosis for Uveitis.

Leveque TK, Goldstein DA.

JAMA Ophthalmol. 2019 Apr 1;137(4):438-439. doi: 10.1001/jamaophthalmol.2018.6202. No abstract available.

PMID:
30589924
19.

Patient-Centered Oncology or Population-Centered Oncology-Which Do We Want, and Which Tradeoffs Are We Willing To Accept?

Goldstein DA, Den RB.

Oncologist. 2019 Mar;24(3):288-290. doi: 10.1634/theoncologist.2018-0679. Epub 2018 Dec 6. No abstract available.

PMID:
30523149
20.

Vertical Hyperreflective Lesions on Optical Coherence Tomography in Vitreoretinal Lymphoma.

Deák GG, Goldstein DA, Zhou M, Fawzi AA, Jampol LM.

JAMA Ophthalmol. 2019 Feb 1;137(2):194-198. doi: 10.1001/jamaophthalmol.2018.5835.

PMID:
30489610
21.

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.

Shlomai A, Leshno M, Goldstein DA.

PLoS One. 2018 Nov 8;13(11):e0207132. doi: 10.1371/journal.pone.0207132. eCollection 2018.

22.

Duration of adjuvant immunotherapy-biologic, clinical and economic considerations.

Stav I, Gyawali B, Goldstein DA.

Med Oncol. 2018 Oct 29;35(12):160. doi: 10.1007/s12032-018-1218-0.

PMID:
30374666
23.

Information Transparency in the Drug Approval Process-Reply.

Gyawali B, Goldstein DA.

JAMA Oncol. 2018 Nov 1;4(11):1622. doi: 10.1001/jamaoncol.2018.4163. No abstract available.

PMID:
30193359
24.

The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis.

Agrawal R, Gunasekeran DV, Agarwal A, Carreño E, Aggarwal K, Gupta B, Raje D, Murthy SI, Westcott M, Chee SP, McCluskey P, Ling HS, Teoh S, Cimino L, Biswas J, Narain S, Agarwal M, Mahendradas P, Khairallah M, Jones N, Tugal-Tutkun I, Babu K, Basu S, Lee R, Al-Dhibi H, Bodaghi B, Invernizzi A, Goldstein DA, Herbort CP, Barisani-Asenbauer T, González-López JJ, Androudi S, Bansal R, Moharana B, Mahajan S, Esposti S, Tasiopoulou A, Nadarajah S, Agarwal M, Abraham S, Vala R, Lord J, Singh R, Sharma A, Sharma K, Zierhut M, Kon OM, Kempen J, Cunningham ET, Rousselot A, Nguyen QD, Pavesio C, Gupta V.

Ocul Immunol Inflamm. 2018 Aug 29:1-11. doi: 10.1080/09273948.2018.1489061. [Epub ahead of print]

PMID:
30156979
25.

Time Is Money: Optimizing the Scheduling of Nivolumab.

Ratain MJ, Goldstein DA.

J Clin Oncol. 2018 Aug 27:JCO1800045. doi: 10.1200/JCO.18.00045. [Epub ahead of print] No abstract available.

PMID:
30148658
26.

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework-Reply.

Ben-Aharon O, Goldstein DA.

JAMA Oncol. 2018 Oct 1;4(10):1438-1439. doi: 10.1001/jamaoncol.2018.3295. No abstract available.

PMID:
30128500
27.

The Influence of Race and Sex on the Side Effect Profile of Methotrexate in the Treatment of Uveitis.

LaMattina KC, Escott SM, Malalis JF, Mai D, Harada Y, Goldstein DA.

Ocul Immunol Inflamm. 2018 Aug 13:1-5. doi: 10.1080/09273948.2018.1498905. [Epub ahead of print]

PMID:
30102096
28.

A real-world analysis of cancer drug wastage due to oversized vials.

Liran O, Prus J, Gordon N, Almog V, Gruenewald T, Goldstein DA.

J Am Pharm Assoc (2003). 2018 Nov - Dec;58(6):643-646. doi: 10.1016/j.japh.2018.06.004. Epub 2018 Jul 13.

PMID:
30017368
29.

Tuberculous Uveitis Presenting with a Bullous Exudative Retinal Detachment: A Case Report and Systematic Literature Review.

Song JH, Koreishi AF, Goldstein DA.

Ocul Immunol Inflamm. 2019;27(6):998-1009. doi: 10.1080/09273948.2018.1485958. Epub 2018 Jul 3.

PMID:
29969330
30.

"Reversible Parkinsonism" following glyphosate exposure.

Goldstein DA, Dunn SE, Karberg K.

Parkinsonism Relat Disord. 2018 Nov;56:107. doi: 10.1016/j.parkreldis.2018.06.012. Epub 2018 Jun 6. No abstract available.

PMID:
29903583
31.

Denosumab for bone lesions in multiple myeloma - what is its value?

Goldstein DA.

Haematologica. 2018 May;103(5):753-754. doi: 10.3324/haematol.2017.185264. No abstract available.

32.

Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.

Sarfaty M, Hall PS, Chan KKW, Virik K, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E, Goldstein DA.

Eur Urol. 2018 Jul;74(1):57-62. doi: 10.1016/j.eururo.2018.03.006. Epub 2018 Mar 22.

PMID:
29576265
33.

The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?

Gyawali B, Goldstein DA.

JAMA Oncol. 2018 May 1;4(5):623-624. doi: 10.1001/jamaoncol.2017.5697. No abstract available.

PMID:
29522146
34.

Relapse of Juvenile Idiopathic Arthritis-Associated Uveitis after Discontinuation of Immunomodulatory Therapy.

Acharya NR, Patel S, Homayounfar G, Enanoria WTA, Shakoor A, Chakrabarti A, Goldstein DA.

Ocul Immunol Inflamm. 2019;27(4):686-692. doi: 10.1080/09273948.2018.1424341. Epub 2018 Feb 16.

PMID:
29451845
35.

Early Steps in the Value of Cancer Care-Many Paths Remain Unexplored.

Goldstein DA, La Vecchia C, Goulart BHL.

Oncologist. 2018 Apr;23(4):391-392. doi: 10.1634/theoncologist.2017-0611. Epub 2018 Feb 7. No abstract available.

36.

Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.

Ben-Aharon O, Magnezi R, Leshno M, Goldstein DA.

JAMA Oncol. 2018 Mar 1;4(3):326-332. doi: 10.1001/jamaoncol.2017.4445.

37.

The Collaborative Ocular Tuberculosis Study (COTS)-1 Report 3: Polymerase Chain Reaction in the Diagnosis and Management of Tubercular Uveitis: Global Trends.

Agarwal A, Agrawal R, Gunasekaran DV, Raje D, Gupta B, Aggarwal K, Murthy SL, Westcott M, Chee SP, McCluskey P, Ling HS, Teoh S, Cimino L, Biswas J, Narain S, Agarwal M, Mahendradas P, Khairallah M, Jones N, Tugal-Tutkun I, Babu K, Basu S, Carreño E, Lee R, Al-Dhibi H, Bodaghi B, Invernizzi A, Goldstein DA, Herbort CP, Barisani-Asenbauer T, González-López JJ, Androudi S, Bansal R, Moharana B, Mahajan S, Esposti S, Tasiopoulou A, Nadarajah S, Agarwal M, Abraham S, Vala R, Singh R, Sharma A, Sharma K, Zierhut M, Kon OM, Cunningham E, Nguyen QD, Pavesio C, Gupta V.

Ocul Immunol Inflamm. 2019;27(3):465-473. doi: 10.1080/09273948.2017.1406529. Epub 2017 Dec 20.

38.

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.

Dudnik E, Moskovitz M, Daher S, Shamai S, Hanovich E, Grubstein A, Shochat T, Wollner M, Bar J, Merimsky O, Zer A, Goldstein DA, Hammerman A, Cyjon A, Shechtman Y, Abu-Amna M, Flex D, Roisman LC, Peled N; Israel Lung Cancer Group.

Lung Cancer. 2018 Dec;126:217-223. doi: 10.1016/j.lungcan.2017.11.015. Epub 2017 Nov 23.

PMID:
29254746
39.

A Policy That Encourages Wastage of Expensive Medications-The JW Modifier.

Goldstein DA, Hirsch A.

JAMA Oncol. 2018 Feb 1;4(2):155-156. doi: 10.1001/jamaoncol.2017.3997. No abstract available.

PMID:
29222558
40.

A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.

Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, Stemmer SM, Rosenbaum E.

Oncotarget. 2017 May 9;8(42):71548-71555. doi: 10.18632/oncotarget.17742. eCollection 2017 Sep 22.

41.

Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.

Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR.

Leuk Lymphoma. 2018 Jul;59(7):1700-1709. doi: 10.1080/10428194.2017.1390230. Epub 2017 Oct 25.

42.

A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.

Goldstein DA, Gordon N, Davidescu M, Leshno M, Steuer CE, Patel N, Stemmer SM, Zer A.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx063.

PMID:
29059432
43.

Trajectories of Injectable Cancer Drug Costs After Launch in the United States.

Gordon N, Stemmer SM, Greenberg D, Goldstein DA.

J Clin Oncol. 2018 Feb 1;36(4):319-325. doi: 10.1200/JCO.2016.72.2124. Epub 2017 Oct 10.

PMID:
29016226
44.

Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen.

Goldstein DA.

JAMA Oncol. 2017 Dec 1;3(12):1628-1629. doi: 10.1001/jamaoncol.2017.3123. No abstract available.

PMID:
28983562
45.

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.

Sarfaty M, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E, Goldstein DA.

Eur Urol. 2018 Apr;73(4):628-634. doi: 10.1016/j.eururo.2017.07.041. Epub 2017 Aug 12.

PMID:
28807351
46.

Fundus Autofluorescence Findings in Eyes With Birdshot Chorioretinitis.

Böni C, Thorne JE, Spaide RF, Ostheimer TA, Sarraf D, Levinson RD, Goldstein DA, Rifkin LM, Vitale AT, Jaffe GJ, Holland GN.

Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4015-4025. doi: 10.1167/iovs.17-21897.

47.

Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.

Zeichner SB, Goldstein DA, Kohn C, Flowers CR.

J Gastrointest Oncol. 2017 Jun;8(3):513-523. doi: 10.21037/jgo.2016.04.03. Review.

48.

Reply to Á. Benedict et al.

Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR.

J Clin Oncol. 2017 Sep 10;35(26):3086-3087. doi: 10.1200/JCO.2017.74.5273. Epub 2017 Jul 17. No abstract available.

PMID:
28715248
49.

Multiple Sclerosis-Associated Uveitis.

Cunningham ET Jr, Pavesio CE, Goldstein DA, Forooghian F, Zierhut M.

Ocul Immunol Inflamm. 2017 Jun;25(3):299-301. doi: 10.1080/09273948.2017.1334469. No abstract available.

PMID:
28696171
50.

Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?

Goldstein DA, Bilal U, Prasad V.

Cancer. 2017 Oct 15;123(20):3872-3874. doi: 10.1002/cncr.30868. Epub 2017 Jun 29. No abstract available.

Supplemental Content

Loading ...
Support Center